AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-255023754/abbott-japan-and-eisai.html" title="Facts and information about Abbott Japan and Eisai Co Ltd receive approval to market the pancreatic digestive enzyme replacement drug Lipacreon (pancrelipase) in Japan.">Abbott Japan and Eisai Co Ltd receive approval to market the pancreatic digestive enzyme replacement drug Lipacreon (pancrelipase) in Japan.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
Abbott Japan and Eisai Co Ltd receive approval to market the pancreatic digestive enzyme replacement drug Lipacreon (pancrelipase) in Japan.
Abbott Japan Co Ltd (Abbott) and Eisai Co Ltd have announced that they have received approval to market the pancreatic enzyme replacement drug Lipacreon (pancrelipase) in Japan as a pancreatic digestive enzyme …
Related articles from newspapers, magazines, journals, and more
-
- Abbott Japan, Eisai launch pancreatic digestive enzyme replacement in Japan.
-
News wire article from: Europe Intelligence Wire
August 30, 2011
700+ words
-
- Abbott Japan and Eisai receive approval to market the pancreatic digestive...
-
News wire article from: Chemical Business Newsbase
April 22, 2011
700+ words
-
- Approval of three new drugs including Olmes recommended: Japan. [1 table].
-
News wire article from: Asia Africa Intelligence Wire
December 15, 2003
700+ words
